Concepedia

Publication | Closed Access

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study

DOI

57

Citations

23

References

2012

Year

Michael P. Manns, Edward Gane, M. Rodríguez‐Torres, Albrecht Stoehr, Chau‐Ting Yeh, Patrick Marcellin, Richard T. Wiedmann, Peggy Hwang, Luzelena Caro, Richard J. O. Barnard,
Hepatology

Abstract

Vaniprevir is a potent HCV protease inhibitor with a predictable resistance profile and favorable safety profile that is suitable for QD or BID administration.

References

YearCitations

Page 1